820
Participants
Start Date
January 10, 2019
Primary Completion Date
November 21, 2019
Study Completion Date
November 11, 2020
Nolasiban
Nolasiban single oral administration
Placebo
Placebo single oral administration
Site 1001, Brussels
Site 1002, Brussels
Site 1003, Brussels
Site 1004, Brussels
Site 1404, Burnaby
Site 1401, Montreal
Site 1402, Toronto
Site 1403, Toronto
Site 1107, Olomouc
Site 1101, Prague
Site 1102, Prague
Site 1103, Prague
Site 1104, Prague
Site 1105, Prague
Site 1108, Prague
Site 1110, Prague
Site 1109, Teplice
Site 1106, Zlín
Site 1204, Copenhagen
Site 1205, Herlev
Site 1202, Hvidovre
Site 1203, Skive
Site 1302, Tallinn
Site 1301, Tartu
Site 1303, Tartu
Site 1504, Berlin
Site 1506, Berlin
Site 1505, Bielefeld
Site 1501, Heidelberg
Site 1502, Lübeck
Site 1503, Marburg
Site 1601, Budapest
Site 1603, Budapest
Site 1602, Tapolca
Site 1703, Bialystok
Site 1705, Bialystok
Site 1702, Katowice
Site 1701, Krakow
Site 1704, Szczecin
Site 1706, Warsaw
Site 1901, Moscow
Site 1905, Moscow
Site 1904, Samara
Site 1902, Yekaterinburg
Site 1805, Barcelona
Site 1808, Barcelona
Site 1809, Leioa
Site 1804, Madrid
Site 1807, Madrid
Site 1811, Seville
Lead Sponsor
ObsEva SA
INDUSTRY